James Netterville
Faculty Member

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W
Cancer Discov. 2012 2 (9): 791-7

PMID: 22798288 · PMCID: PMC3449158 · DOI:10.1158/2159-8290.CD-12-0097

UNLABELLED - Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40% to 50% of cases are positive. To uncover other potential targetable mutations, we conducted whole-genome sequencing of a highly aggressive BRAF (V600) and KIT (W557, V559, L576, K642, and D816) wild-type melanoma. Surprisingly, we found a somatic BRAF(L597R) mutation in exon 15. Analysis of BRAF exon 15 in 49 tumors negative for BRAF(V600) mutations as well as driver mutations in KIT, NRAS, GNAQ, and GNA11, showed that two (4%) harbored L597 mutations and another two involved BRAF D594 and K601 mutations. In vitro signaling induced by L597R/S/Q mutants was suppressed by mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibition. A patient with BRAF(L597S) mutant metastatic melanoma responded significantly to treatment with the MEK inhibitor, TAK-733. Collectively, these data show clinical significance to BRAF(L597) mutations in melanoma.

SIGNIFICANCE - This study shows that cells harboring BRAF(L597R) mutants are sensitive to MEK inhibitor treatment, providing a rationale for routine screening and therapy of BRAF(L597R)-mutant melanoma.

MeSH Terms (13)

Aged Cell Line, Tumor Genome, Human Humans Male MAP Kinase Kinase Kinases MAP Kinase Signaling System Melanoma Mutation Protein Kinase Inhibitors Proto-Oncogene Proteins B-raf Pyridones Pyrimidinones

Connections (6)

This publication is referenced by other Labnodes entities: